Afuco™ Anti-Human Integrin α5β3 ADCC Therapeutic Antibody (VPI-2690B), ADCC Enhanced
Anti-Integrin α5β3 ADCC Enhanced Antibody (VPI-2690B) is an ADCC enhanced antibody produced by our Afuco™ platform. VPI-2690B is a first-in-class subcutaneously (under the skin) administered monoclonal antibody with a unique mechanism of action. VPI-2690B binds to a very specific target in the kidney, the C-loop domain sequence within a cell's α5β3 receptor. To date, Vascular Pharmaceuticals has completed an ascending single/multiple dose Phase 1 study of VPI-2690B in healthy volunteers. The results showed that the drug is safe with significant levels of drug exposure and exhibited a consistent, predictable safety profile. A Phase 2 clinical trial is currently ongoing and is enrolling new patients.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-426CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | Integrin α5β3 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided. |